The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
The DOI matches its Crossref record.
Abstract
BACKGROUND: Approximately 50% of patients diagnosed with major depressive disorder will experience a recurrent or chronic course of illness for which long-term treatment is recommended. Moreover, at least 20% of patients diagnosed with depression do not respond satisfactorily to several traditional antidepressant medication treatment trials. Very little is known about the health care costs of patients with treatment-resistant depression. METHOD: Based on medical claims data (MarketScan Research Database, The MEDSTAT Group, Cambridge, Mass.) from January 1, 1995, to June 30, 2000, a naturalistic, retrospective analysis was conducted to study the characteristics and health care utilization of patients with treatment-resistant depression. All patients having an International Classification of Diseases, Ninth Revision (ICD-9), diagnosis code for unipolar or bipolar depression with specified antidepressant dosing and treatment durations were initially selected. Patients were then classified as "treatment resistant" if either they switched from or augmented initial antidepressant medication with other antidepressants at least twice (outpatient treatment-resistant group) or they switched from or augmented their initial antidepressant medication and also had a claim for either a depression-related hospitalization or suicide attempt (hospitalized treatment-resistant group). Those meeting the initial medication and diagnosis selection criteria but not meeting the treatment-resistance criteria constituted the comparison group. Members of the comparison group had comparatively stable antidepressant medication use patterns, consistent with an acceptable response to treatment. Patients were followed for a minimum of 9 months. Resource utilization was calculated from index date to last available claims data point and then annualized. RESULTS: Treatment-resistant patients were more likely to be diagnosed with bipolar disorder or concurrent substance abuse or anxiety disorders than the comparison group (p <.001). Treatment-resistant patients were at least twice as likely to be hospitalized (general medical and depression related) and had at least 12% more outpatient visits (p <.02). Treatment resistance was also associated with use of 1.4 to 3 times more psychotropic medications (including antidepressants) (p <.001). Patients in the hospitalized treatment-resistant group had over 6 times the mean total medical costs of non-treatment-resistant depressed patients ($42,344 vs. $6512) (p <.001) and their total depression-related costs were 19 times greater than those of patients in the comparison group ($28,001 vs. $1455) (p <.001). CONCLUSION: Treatment-resistant depression is costly and associated with extensive use of depression-related and general medical services. These findings underscore the need for early identification and effective long-term maintenance treatment for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, for approximately 50% of those who suffer from depression, their illness will follow a chronic, relapsing course associated with considerable disability and impairment (Crown 2002).”
From Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents (2012) · cites this paper as Crown 2002
In the citing paper
“Direct medical costs associated with TRD are estimated to be 2-6 times higher compared with other patients with MDD, 42, 43 with costs increasing with chronicity and severity of TRD. 44”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
In the citing paper
“Patients with TRD are twice as likely to be hospitalised compared with non-TRD patients, and require increased numbers of psychiatric outpatient visits. 43”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
Citations
Cited by
Items 301–382 of 382
Antidepressant treatment patterns and costs among US employees
Birnbaum, H. G., Greenberg, P. E., Tang, J., Hsieh, M., Wu, E. Q., Amand, C., & Ben-Hamadi, R. (2009) · Journal of Medical Economics · doi:10.3111/13696990902757389 · Cited by 3
Interpersonal mechanisms in recurrence of depression
Bos, E. H. (2005) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 4
Defining and Differentiating Treatment-Resistant Depression
Treviño, K. (2012) · Cited by 3
Ngabo-Woods, H., Dunai, L., & Verdú, I. S. (2025) · Applied Sciences · doi:10.3390/app152312524 · Cited by 3
A Multimodal Framework for Prognostic Modelling of Mental Health Treatment and Recovery Trajectories
Ngabo-Woods, H., Dunai, L., Verdú, I. S., & Sui, L. (2026) · Applied Sciences · doi:10.3390/app16020763 · Cited by 4
Porceddu, G., Pessina, E., Cattaneo, C. I., Martiadis, V., Bianca, C., Maina, G., & Rosso, G. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1744056 · Cited by 2
“Individuals with TRBD often suffer from prolonged depressive episodes, elevated suicide risk, diminished occupational and social engagement, and poor treatment adherence — factors that contribute to increased hospitalization, unemployment, and a range of psychiatric and physical comorbidities (34).”
Wilkinson, S. T., Prashad, S., Dalthorp, R., Harding, L., Kitay, B. M., Parikh, S. V., Dziura, J. D., Clayton, A. R., Fram, G., Lepoutre, V., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108273 · Cited by 2
Altinişik, İ., Karimi, A., Sun, E., & Molina, J. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121716 · Cited by 3
Conway, C. R., Sackeïm, H. A., Rush, A. J., Bunker, M. T., Gordon, C., Kriedt, C. L., & Aaronson, S. T. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251339 · Cited by 2
Self-citationUtilization of Ketamine for Major Depression
Dao, R., & Aggarwal, A. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00027 · Cited by 2
The Role of Ketamine in Treatment-resistant Depression: A Narrative Review
Reddy, A., Patel, S. G., Barik, A. K., Thappa, P., Jangra, K., Kaur, K., Chauhan, R., & Luthra, A. (2024) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2024.00003 · Cited by 4
The economic burden of treatment-resistant depression: Cost-of-illness perspective
Niazi, S. K., & Bobo, W. V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00003-7 · Cited by 3
Epidemiology and Burden of Treatment-Resistant Depression in Colombia: Analysis of the TRAL Study
Cordoba-Rojas, R., Ferro, E., Baena, L. M. A., KANEVSKY, G. A., & Cabrera, P. (2023) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2023.04.009 · Cited by 3
Coexisting Depression and Anxiety: Classification and Treatment
Kulhan, T., Ondrejka, I., Ordaz, J., Šnircová, E., & Nosalova, G. (2012) · Acta Medica Martiniana · doi:10.2478/v10201-011-0035-3 · Cited by 2
“The impairment and health care utilization associated with untreated mixed anxiety–depression is significant, and recognition and treatment of these patients are important (33).”
BackgroundTreatment resistance in first-episode psychosis
Huber, C. G., & Lambert, M. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511576287.021 · Cited by 2
Genetic markers anticipate response to citalopram in a majority of patients
Alemi, F., Zargoush, M., Erdman, H. P., Vang, J., Epstein, S., & Ayman, F. (2011) · Psychiatric Genetics · doi:10.1097/ypg.0b013e3283480485 · Cited by 2
“Poorly responsive or untreated patients are twice as likely to be hospitalized and incur 19 times greater cost than patients with effectively treated (Crown et al., 2002).”
BackgroundTraditional Plant Compounds for the Treatment of Neuropsychiatric Disorders
Din, I., Anwar, M., Rayees, S., & Malik, F. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-1761-7_18 · Cited by 2
Khan, Z., Saif, A., & Parveen, A. (2023) · NeuroRegulation · doi:10.15540/nr.10.3.186 · Cited by 1
“Up to half of such population do not respond to first-line antidepressant treatment and one-third do not respond to two or more treatments (Trivedi et al., 2006), making it prevalent and therefore resulting in added patient suffering, disability, and suicide risk (Crown et al., 2002).”
Vagus Nerve Stimulation for Severe Depression
(2007) · Psychiatric Annals · doi:10.3928/00485713-20070301-03 · Cited by 2
Treatment of bipolar depression: focus on pharmacologic therapies
Mitchell, P. B., & Malhi, G. S. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.1.69 · Cited by 2
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
Inhaled gases for treatment-resistant major depression
Conway, C. R., Mickey, B. J., Palanca, B. J. A., Tadler, S. C., & Nägele, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00033-5 · Cited by 2
Sheline, Y. I., Batzdorf, A. S., Makhoul, W., Balderston, N. L., Lynch, K. G., Cash, R. F. H., & Liston, C. M. (2026) · Transcranial magnetic stimulation . · doi:10.1016/j.transm.2026.100205 · Cited by 1
Cuomo, A., McIntyre, R. S., Koukouna, D., Pinzi, M., Pardossi, S., Firenzuoli, B., Barillà, G., Carmellini, P., Alamia, A., & Fagiolini, A. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261437597 · Cited by 1
Pompili, M., Sarubbi, S., Biase, G. D., Roberto, P., Fascetti, W., Trocchia, M. A., Erbuto, D., & Berardelli, I. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.09.005 · Cited by 1
Deep Brain Stimulation for Treatment-Resistant Depression: A State-of-the-Art Review
Meguins, L. C. (2012) · InTech eBooks · doi:10.5772/33416 · Cited by 1
“Treatment-resistant depression has an estimated prevalence of 2-5% and continued depressive symptoms are directly responsible to ongoing functional impairment, increased utilization of health care resources, a high risk of suicide and an overall increased mortality (12-14).”
BackgroundNetwork Modulation in Neuropsychiatric Disorders Using the Virtual Brain
Protzner, A. B., An, S., & Jirsa, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-59797-9_8 · Cited by 2
Adu, M. K., Dias, R. D. L., Agyapong, B., Eboreime, E., Sapara, A. O., Lawal, M. A., Chew, C., Frost, K. D., Li, D., Flynn, M., et al. (2023) · JMIR Research Protocols · doi:10.2196/46830 · Cited by 1
“Furthermore, the overall depression-related cost among patients with TRD is estimated to be about 19 times greater compared to that among patients with other depressive conditions [22].”
InfluentialLa stimulation du nerf vague (SNV)
Fovet, T., Bubrovszky, M., & Poulet, E. (2014) · Springer eBooks · doi:10.1007/978-2-8178-0505-4_8 · Cited by 1
Ameli, O., Soria-Saucedo, R., Smith, E. G., Cabral, H., Bori, M. S., & Kazis, L. E. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000687 · Cited by 1
“Despite absence of a universal definition for treatment resistance,(1,3,20,21) treatment switch and augmentation have been used as a measure of inadequate response.(22,23) Crown et al(23) used both treatment switching as well as augmentation for a measure of treatment resistance in inpatient and outpatient claims data.”
MethodDepression and Chronic Medical Illness: New Treatment Approaches
Chang, T. E., & Boyden, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_3 · Cited by 1
Anxiety Diagnoses and Their Relationship to the Number of Prescribed Psychotropic Medications
Sansone, R. A., Gaither, G. A., & Rytwinski, D. (2004) · Journal of Mental Health Counseling · doi:10.17744/mehc.26.3.ug2hm2fam23wx1vf · Cited by 1
Treatment-resistant mood disorders
Passos, I. C., & Quevedo, J. (2015) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000054 · Cited by 1
Depressionsforschung zwischen Verweigerung und Anpassung
Leuzinger‐Bohleber, M. (2005) · Vandenhoeck & Ruprecht eBooks · doi:10.13109/9783666451638.11 · Cited by 1
Voineskos, D. (2019) · TSpace (University of Toronto) · Cited by 1
Lee, C. T., Palacios, J. E., Richards, D., Hanlon, A. K., Lynch, K., Harty, S., Claus, N., Swords, L., O’Keane, V., Stephan, K. E., et al. (2022) · doi:10.31234/osf.io/4j6z8 · Cited by 1
A Snapshot of the Mental Health of Software ProfessionalsPreprint
de Almeida, E. S., Nunes, I., de Oliveira, R. P., Carvalho, M. L. L., Brunoni, A. R., Rong, S., & Ahmed, I. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4849630 · Cited by 3
Herrera, M. (2013) · Lincoln (University of Nebraska) · Cited by 1
Revista Brasileira de Psiquiatria
Lepine, B. A., Moreno, R. A., Campos, R. N., & Couttolenc, B. F. (2012)
Cao, Z., Zou, K. H., Baker, C. L., Su, J., & Paulose‐Ram, R. (2011)
Park, J. W., Kim, W., Shin, K.-M., & Noh, J. S. (2014) · 대한정신약물학회지
Eficácia terapêutica do exercício físico associado à farmacoterapia na depressão maior
Siqueira, C. C. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2015.tde-05102015-115449
Serafini, G., Hayley, S. P., Ghasemi, M., & Amore, M. (2017) · Wiley eBooks · doi:10.1002/9783527803781.ch11
Vergleichende Psychotherapieforschung bei Depressionen
Böker, H. (2005) · Vandenhoeck & Ruprecht eBooks · doi:10.13109/9783666451645.258
Methylphenidate augmentation during antidepressant treatment for depression in HIV: a case report
Primatanti, A. (2018) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/434/1/012331
“In this case, the administration of additional medications might be necessary to help maintaining and even improving patients’ quality of life [4].”
BackgroundNeuroendocrine studies in patients with affective disorders
Bendix, M. (2019) · DiVA at Umeå University (Umeå University)
難治性うつ病に対する反復性経頭蓋磁気刺激療法(rTMS)および磁気けいれん療法(MST)の臨床応用
野田, 賀. (2016) · 総合病院精神医学 · doi:10.11258/jjghp.28.132
Characteristics of premorbid stage in patients with treatment-resistant depression
Chiriță, V., Chiriță, R., & Cărăușu, G. (2019) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2019.03.05
Shah, D. (2019) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.3855
Zhang, Z. L. H., Li, Z. W. J., LanMinling, X., & Huang, Z. (2015)
Tamayo, J. M., Ruiz, Y. P., & Ruíz, I. (2016) · Archivos de Neurociencias
Il ruolo della terapia psicodinamica e gli ostacoli alla sua diffusione
Lazar, S. G. (2021) · PSICOTERAPIA E SCIENZE UMANE · doi:10.3280/pu2021-004004
Areán, P. A., & Ayalon, L. (2009) · Springer eBooks · doi:10.1007/978-0-387-09757-2_23 · Cited by 2
Leuzinger‐Bohleber, M. (2009) · Zeitschrift für Individualpsychologie · doi:10.13109/zind.2009.34.3.246
Privitera, M. R., & Lyness, J. M. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2261-9.50030-6
Stranger Danger! The Role of Ghrelin in Modulation of Social Behavior
Park, S. (2017) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2017-12211
Ontiveros, J. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82568
“Resistance to major depressive disorder treatment, but also to other depressive disorders, such as dysthymia and bipolar depression, causes distress to patients and their relatives, and increases the number of hospital admissions, outpatient consultations, the use of psychoactive drugs, and treatment costs up to six t…”
Lepine, B. A. (2004) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.6.2004.tde-05102022-175554
Therapy management of treatment-resistant depression
Moraru, C., Rădulescu, I.-D., Marusic, R.-I., Oroian, B. A., Nechita, P., & Rusu-Zota, G. (2022) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2022.4.08
“Hospitalization is twice as common in those with TRD, and it costs more than six times as much as it does for depressive patients who are not treatment-resistant (10).”
Into the Wild: Reflecting on Neuroethics as Innovation Moves from the Laboratory to Society
Saville, D., Kim, A., Enriquez, J., Rommelfanger, K. S., McCullough, M. E., Nguyen, C., & Dada, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-14339-7_11
Linking major depressive disorder pathogenesis with kynurenine pathway - a literature review
SZAWICA, D., Kuźniar, A., Fularska, K., Oleszko, M., & WĄSIEWICZ, E. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.15.01.003
Caldieraro, M. A., Teng, C. T., Lacerda, A. L. T., Quarantini, L. C., Grabowsiky, H., KANEVSKY, G. A., & Perocco, S. (2023) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v15.n1.p39-51
The use of inhaled gases in psychiatry
Hristidis, V. C., Nägele, P., Palanca, B. J. A., Tadler, S. C., Mickey, B. J., Gott, B. M., & Conway, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00016-1
Neuromodulation of disrupted brain networks
Klooster, D., Leunissen, I., Tik, M., Baeken, C., & Sack, A. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-820480-1.00190-x
Chapter 6. Psychotherapy in the Treatment of Depression
Lazar, S. G. (2010) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780873182553.lg06
Laaboub, N., Ranjbar, S., Crettol, S., Ansermot, N., Vandenberghe, F., Grandjean, C., Piras, M., Elowe, J., Preisig, M., von Gunten, A., et al. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2025.10036 · Cited by 1
“In addition, LOS are influenced by the illness ’ s level of complexity (notably psychotic disorders) [10], and treatment compliance or resistance [11].”
Chronotherapeutics for treatment-resistant depression
Dallaspezia, S., & Benedetti, F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00035-9
Epidemiology and Burden of Treatment-Resistant Depression in Colombia: Analysis of the TRAL Study
Cordoba-Rojas, R., Ferro, E., Baena, L. M. A., KANEVSKY, G. A., & Cabrera, P. (2025) · Revista Colombiana de Psiquiatría (English ed ) · doi:10.1016/j.rcpeng.2025.10.007 · Cited by 2
Zhang, Q., Xiaowen, G., Li, W., Xiangqi, K., Haodong, W., Zheng, Y., Limin, Y., Jia, J., Mengmeng, S., Chaojuan, M., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07584-8
“Furthermore, TRD patients incur substantially higher healthcare costs than non-TRD patients, as reflected in increased hospitalization rates and more frequent attempts with diverse pharmacological treatments [17–19].”
Tang, J., Zheng, W., Ouyang, Y., Dong, J., & Qin, B. (2025) · Neurological Research · doi:10.1080/01616412.2025.2592116
Chen, L., Thomas, E., & Cerins, A. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-26602-7.00030-0
Lee, C. T., Palacios, J. E., Richards, D., Hanlon, A. K., Lynch, K., Harty, S., Claus, N., Swords, L., O’Keane, V., Stephan, K. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22612702
Lee, C. T., Palacios, J. E., Richards, D., Hanlon, A. K., Lynch, K., Harty, S., Claus, N., Swords, L., O’Keane, V., Stephan, K. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22612705
Shin, D., Kim, N. W., Kim, M. J., Rhee, S. J., Park, C. H. K., Kim, H., Yang, B. R., Kim, M.-S., Choi, G. J., Koh, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12096774
Othman, S. B., & Nasr, M. B. (2026) · Middle East Current Psychiatry · doi:10.1186/s43045-026-00627-0
Richieri, R. M. (2014) · theses.fr (ABES) · doi:10.70675/5d3af1abz1fd4z4313za06ez97c949a8fb85
Depresyon Tanıdan Tedaviye Klinik Süreç
Gül, V. (2026) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.4140
Rush, S., & Nasrallah, H. A. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2675008
“Together with inflammatory models, these findings suggest that impaired neuroplasticity and network dysregulation represent one pathway among several overlapping biological processes contributing to depressive illness and treatment resistance [25–27].”
Wang, Y., Storaci, A. S., Alexander, G. C., & Gibbons, J. B. (2026) · Drug Safety · doi:10.1007/s40264-026-01722-1
Hasanieh, K. A., Zorumski, C. F., Sackeim, H. A., Bunker, M. T., Aaronson, S. T., Rush, A. J., & Conway, C. R. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00797-1
“Compared to patients with treatment-responsive MDD, TRD patients have greater morbidity [5], disability [6], higher rates of relapse [2], psychiatric hospitalization [7], greater psychiatric costs [7], more frequent attempted/complete suicide [8], and higher rates of substance use disorders [9].”
Self-citationNeuroscience-informed psychoeducation for depression: From stress to adaptive brain recovery
Juruena, M. F. (2026) · Progress in brain research · doi:10.1016/bs.pbr.2026.08.007
Metadata
- Authors
- Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-11-15
- Volume
- 63
- Issue
- 11
- Pages
- 963-971
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2098750661
- Cited by
- 386
- References
- 0
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 13 · 2023: 23 · 2022: 20 · 2021: 17 · 2020: 17 · 2019: 18 · 2018: 16 · 2017: 9 · 2016: 15 · 2015: 17 · 2014: 19 · 2013: 19 · 2012: 17
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, major depressive disorder, bipolar disorder, health care utilization, health care costs, antidepressants, hospitalization, psychotropic drug use, substance use comorbidity, anxiety disorders, health insurance claims data, suicide attempts, outpatient visits, chronic depression, recurrent depression
- MeSH terms
- Adult, Ambulatory Care, Bipolar Disorder, Costs and Cost Analysis, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Patient Admission, Psychotropic Drugs, Referral and Consultation, Retrospective Studies, Utilization Review, Comorbidity, Drug Costs, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.